Sepsis-induced myeloid-derived suppressor cells (MDSCs) contribute to immunosuppression associated with sepsis. We reported that the CCAAT enhancer-binding protein C/EBPβ activates microRNA (miR)-21 and miR181b expressions, which induce transcription factor NFI-A to support the generation and expansion of MDSCs in the bone marrow and spleens of septic mice. Here, using a conditional knockout mouse model lacking C/EBPβ in the myeloid lineage, we find that without C/EBPβ, myeloid progenitor cells could not express miR-21 or miR181b, and ectopic expression of C/EBPβ in the C/EBPβ-deficient myeloid progenitors activated the expression of the two miRNAs. Moreover, C/EBPβ-reconstituted myeloid cells expressed IL-10 and reduced T cell proliferation and function, similar to control MDSCs that express C/EBPβ. Exogenous expression of miR-21 and miR-181b in the C/EBPβ-deficient myeloid progenitors from septic mice produced similar results. Notably, NFI-A-dependent transactivation of NF-kB MDSC generating pathway was reversed in the C/EBPβ-deficient myeloid progenitors from septic mice. Together, these results support that decreasing C/EBPβ expression prevents MDSC generation and decreases immunosuppression in septic mice, providing a target for sepsis treatment.
Introduction
The early inflammatory response to sepsis is characterized by a hyperinflammatory reaction that, if not treated early, progresses to a protracted immunosuppressive phase, which alters both innate and adaptive immunity (Hotchkiss et al., 2013b; Liu et al., 2012; Remick, 2007) . At the cellular level, sepsis-induced immunosuppression is associated with tolerance of monocytes/macrophages and neutrophils as demonstrated by their decreased responses to bacterial toxins and failure to clear microbial infections (Alves-Filho et al., 2010; Ellaban et al., 2004) , depletion of adaptive immune effector cells by apoptosis (Hotchkiss et al., 2013b; Oberholzer et al., 2001; Wesche et al., 2005) , and suppression of T cell proliferation and function (Boomer et al., 2011; Guignant et al., 2011) .
Our previous studies in a mouse model of polymicrobial sepsis induced by cecal ligation and puncture, which develops into early and late sepsis phases, revealed substantial expansion of myeloid-derived suppressor cells (MDSCs) within the bone marrow and spleen during the late septic phase (Brudecki et al., 2012a) . We reported that immature Gr1 + CD11b + myeloid cell from late septic mice (i.e., MDSCs)
produce immunosuppressive mediators, inhibit T cell activation and proliferation, and are unable to differentiate into mature immune cells (McClure et al., 2016 (McClure et al., , 2014 . MicroRNA (miR)-21 and miR-181b inhibit MDSCs differentiation during sespsis by inducing the myeloid cell differentiation-related transcription factor NFI-A (McClure et al., 2016) . In vivo inhibition of miR-21 and miR-181b in septic mice decreases repressor MDSCs and improves late sepsis survival (McClure et al., 2014) . The CCAAT enhancer-binding transcription factor C/EBPβ supports inflammation-induced proliferation of myeloid cells, where it accelerates myelopoiesis induced by cytokines or infections (Hirai et al., 2006; Marigo et al., 2010) . For example, cytokines and growth factors, such as IL-6, G-CSF and GM-CSF, produced during infection or in tumor microenvironment can induces C/EBPβ expression (Manz and Boettcher, 2014; Marigo et al., 2010; Zhang et al., 2010) . Previous studies have shown that activation of the transcription factor Stat3 by G-CSF or IL-6 is required for induction of C/EBPβ transcription in mouse myeloid progenitors (Hirai et al., 2006; Niehof et al., 2001 ). In addition, the transcription factor CREB (cAMP-response elementbinding protein) is also required for the IL-6 mediated induction of C/ EBPβ transcription by tethering Stat3 at the C/EBPβ promoter (Niehof et al., 2001) . In support of the important role of Stat3 in the induction of C/EBPβ, recent studies have shown that the phenotype of bone marrow conditional Stat3 knockout mice resembles C/EBPβ deficiency since it exhibits impaired accelerated myelpoiesis under the pathophysiological conditions (Hirai et al., 2006; Panopoulos et al., 2006) .
We previously reported that C/EBPβ in conjunction with Stat3 binds to and activates the promoters of both miR-21 and miR-181b in naive Gr1 + CD11b + cells (McClure et al., 2017) , which are phenotypically similar to MDSCs. We hypothesized that C/EBPβ triggers the miR-21 and miR-181b dependent path that generates MDSCs during late sepsis immunosuppression. In this study, we used a mouse model with conditional deletion of Cebpb gene in the myeloid lineage to further investigate the mechanism of C/EBPβ-induced generation of MDSCs in sepsis. We find that C/EBPβ induces miR-21 and miR-181b expression to drive MDSCs during sepsis. Notable, myeloid precursors generated in the C/EBPβ conditional knockout mice during sepsis differentiate into competent innate immune cells, supporting that targeting the C/EBPβ-mediated pathway may prevent late sepsis immunsuppression.
Materials and methods

Mice
Generation of BALB/c Cebpb conditional, myeloid cell-specific knockout mice have been described previously (McPeak et al., 2017 
Induction of sepsis
Polymicrobial sepsis was induced by cecal ligation and puncture (CLP). CLP was performed using a 21-gauge needle and two punctures, and mice were administered antibiotic to generate early/acute and late/chronic septic phases as described previously (Brudecki et al., 2012b) . This model creates a prolonged infection with 100% mortality over 4 weeks. To generate late sepsis, mice were subcutaneously administered antibiotic (Imipenem; 25 mg/kg body weight) or an equivalent volume of 0.9% saline. To establish intra-abdominal infection and approximate the clinical situation of early human sepsis where there often is a delay between the onset of sepsis and the delivery of therapy (Mazuski et al., 2002) , injections of Imipenem were given at 8 and 16 h after CLP, which results in high mortality (∼60-70%) during the late/chronic phase (Brudecki et al., 2012b) . The presence of early sepsis was confirmed by transient systemic bacteremia and elevated cytokine levels in the first 5 days after CLP. Late/chronic sepsis (after day 5) was confirmed by enhanced peritoneal bacterial overgrowth and reduced circulating proinflammatory cytokines.
Isolation of Gr1
+ CD11b + cells
Gr1
+ CD11b + cells were isolated from the bone marrow using magnetically assisted cell sorting according to the manufacturer's protocol (Miltenyi Biotech, Auburn, CA). The bone marrow cells were flushed out of the femurs with RPMI-1640 medium (without serum) under aseptic conditions (Brudecki et al., 2012b) . A single cell suspension of the bone marrow was made by pipetting up and down and filtering through a 70-μm nylon strainer, followed by incubation with erythrocyte lysis buffer. 
CD11b
+ cells were cultured in RPMI-1640 medium (Invitrogen, Carlsbad, CA) supplemented with 100 U/ml penicillin, 100 μg/ml streptomycin, 2 mM L-glutamine (all from Hyclone Laboratories, Logan, UT), and 10% fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA) at 37°C and 5% CO 2 .
ELISA
Cytokine production was determined using enzyme-linked immunosorbent assay (ELISA) kits (eBioscience) according to the manufacturer's instructions. Each sample was run in duplicate.
C/EBPβ expression plasmid
Full length mouse Cebpb cDNA (transcript variant 1) was cloned in pEZ-M02 expression vector downstream of the CMV promoter, and C/ EBPβ protein expression was verified by western blotting. A pReceiver-M02 vector served as a negative control.
Transfection of C/EBPβ plasmid and miRNA precusors
Plasmid DNA was suspended in HiPerFect reagent (Qiagen, Valencia, CA) (final concentration: 0.5 μg/ml). For miR-21 and miR181b overexpression, negative control precursor or miR-21 or miR181b precursor (Ambion) were suspended in a HiPerFect reagent at 50 nM final concentration. Gr1 
CD11b
+ cells were transfected using the Gene Pulser MXCell system (Bio-Rad, Herclues, CA). After 24 h, portions of the cells were removed and either used for RNA isolation and miRNA measurements by PCR or stimulated for 12 h with 1 μg/ml of LPS, and culture supernatants were used for cytokine measurements by ELISA. The remainder of the cells was differentiated for 6 days with M-CSF plus rIL-4 and then analyzed by flow cytometry. For Stat3 knockdown, Gr1 + CD11b + cells were transfected with pools of Stat3-specific or scrambled (control) siRNAs (Santa Cruz Biotechnology) at a 0.5 μM final concentration as described above and then incubated for 36 h.
miRNA measurement
Expression levels of miR-21 and miR-181b were determined by quatitative real-time PCR (RT-qPCR) using miRNA-enriched RNA and miScript SYBR Green PCR kit with miScript Primer Assays specific to miR-21 and miR-181b according to the manufacturer's instructions (Qiagen). The relative expression was calculated using the 2 −ΔΔCt cycle threshold method after normalization to the endogenous U6 RNA as an internal control.
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed to assess in vivo DNA-protein interactions at the miR-21 and miR-181b promoters using ChIP-IT Express Enzymatic Shearing kit according to the manufacturer's instructions (Active Motif, Carlsbad, CA). Briefly, Gr1 + CD11b + cells were harvested from the bone marrow and protein-DNA complexes were cross-linked by fixation in 1% formaldehyde in minimal culture medium for 10 min at room temperature. After washing with cold PBS, cells were lysed in 1 x lysis buffer containing protease inhibitor cocktail. Cell lysate was cleared by centrifugation at 5000 rpm for 10 min at 4°C. The pelleted nuclei were then resuspended in digestion buffer and incubated with the enzymatic shearing cocktail at 37°C for 10 min. The sheared chromatin solution was recovered by centrifugation at 15,000 rpm for 10 min at 4°C. Ten microliter of the chromatin solution was reserved as "input" DNA sample. The remaining chromatin solution was immunoprecipitated overnight at 4°C with protein G magnetic beads and 3 μg of antibody specific to p-Stat3, C/ EBPα, C/EBPβ, or isotype control antibody (Santa Cruz Biotechnology). The chromatin/antibody complexes captured on the beads were washed three times in ChIP buffer and then eluted by incubation for 15 min in 50 μl elution buffer. Next, the DNA-protein cross-links were reveresed by incubating the eluted chromatin with 50 μl of reverese cross-linking buffer. The supernatant containing the DNA was then incubated, along with the "input" DNA samples at 95°C for 15 min. After treatment with proteinase K for 1 h at 37°C, the reaction was stopped, and the resulting DNA was extracted and stored at −20°C. Enrichment of the miR-21 and miR-181b promoter sequences in the ChIPed DNA was measured by quantitative real-time PCR using primer and fluorescently labeled internal probe sequences (Integrated DNA Technologies, Coralville, IA) specific to the miR-21 and miR-181b promoters, as described previously (McClure et al., 2017) .
Flow cytometry
Cells were stained by incubation for 30 min on ice in staining buffer (PBS plus 2% FBS) with the following antibodies: anti-Gr1 conjugated to FITC, anti-CD11b conjugated to phycoerythrin (PE), anti-F4/80 conjugated to allophycocyanin (APC), anti-CD11c conjugated to PE, anti-MHC II conjugated to FITC, anti-CD4 conjugated to PE (all from eBioscience, San Diego, CA). An appropriate isotype-matched control was used for each antibody. After washing, the samples were analyzed by a FACSCaliber flow cytometer (BD Biosciences, Sparks, MD). About 25,000 events were acquired and analyzed using the CellQuest Pro software (BD Biosciences).
Gr1
+ CD11b + cell differentiation Gr1 + CD11b + cells were cultured for 6 days with complete RPMI-1640 medium in the presence of 10 ng/ml of M-CSF (PeproTech Inc., Rocky Hill, NJ) and 10 ng/ml rIL-4 (eBioscience, San Diego, CA). The cell phenotypes were analyzed by flow cytometry.
T cell proliferation
Gr1 + CD11b + cells were cultured with CD4 + T cells to determine their effects on T cell proliferation and IFN-γ production. Briefly, spleen CD4 + T cells were isolated by positive selection using biotinylated anti-CD4 magnetic beads (Miltenyi). Cells were fluorescently labeled with carboxy-fluorosceindiacetate, succinimidyl ester (CFSE) dye using the Vybrant CFDA SE Cell Tacer Kit (Invitrogen Molecular Probes, Eugene, OR). Cells were incubated for 10 min at room temperature with 10 μM CFSE dye and then co-cultured (at 1:1 ratio) with Gr1 + CD11b + cells. T cell proliferation was induced by the stimulation with an anti-CD3 plus an anti-CD28 (R & D Systems, Minneapolis, MN) antibody (1 μg/ml/ each). After 3 days, cells were harvested and CD4 + T cell proliferation was determined by the step-wise dilution of CFSE dye in dividing, CD3-gated CD4 + cells using flow cytometry. Culture supernatants were collected for the IFN-γ measurement.
Western blot
Equal amounts of protein extracts were mixed with 5× Laemmeli sample buffer, separated by a SDS-10% polyacrylamide gel (Bio-Rad) and subsequently transferred to nitrocellulose membranes (Thermo Scientific, Waltham, MA). After blocking with 5% milk in Tris-buffered saline/Tween-20 for 1 h at room temperature, membranes were probed overnight at 4°C with the appropriate primary antibodies. After washing, blots were incubated with the appropriate HRP-conjugated secondary antibody (Life Technologies, Grand Island, NY) for 2 h at room temperature. Proteins were detected with the enhanced chemiluminescence detection system (Thermo Fisher Scientific). The developed bands were visualized using the ChemiDoc XRS Detection System (Bio-Rad) and the images were captured with the Image Lab Software V3.0. Membranes were stripped and re-probed with b-actin antibody (Sigma-Aldrich) as a loading control. Fig. 1 . Loss of miR-21 and miR-181b expression in C/EBPβ-deficient Gr1 + CD11b + cells during sepsis.
Sepsis was induced by cecal ligation and puncture (CLP) using a 23-gauge needle, and mice were given antibiotics (imipenem) with fluid resuscitation, which produced early (days 1-5) and late (days 6-28) sepsis phases. ), C/EBPβ, C/EBPα, or IgG isotype control antibody. Next, chromatin cross-links were reversed to recover the protein-bound DNA. The purified DNA was amplified by real-time PCR to measure the level of enrichment of miR-21 and miR-181b sequences in the immunoprecipitated complexes using promoter-specific primer/probe sets. PCR reactions were performed in triplicate. Samples were normalized to the "input" DNA (i.e., DNA isolated before immunoprecipitation) and are presented as fold enrichment relative to the IgG-immunoprecipitated samples (set at 1-fold). Data are expressed as mean ± s.d. (*p < 0.05) of 5 mice per group and represent one of two experiments. *, compared with IgG. cKO, conditional knockout.
Statistical analysis
All data are expressed as mean ± s.d. and were analyzed by Microsoft Excel, V3.0. Differences among groups were analyzed by a two-tailed student's t test for two groups and by ANOVA for multiple groups. Statistical significance was designated at p < 0.05. (Fig. 1B) , concurrent with the miRNA induction. In (Fig. 1B, lower panel) . These results demonstrate that in the absence of C/EBPβ expression, C/EBPα binds to and activates the miR-21 and miR-181b promoters in sepsis Gr1 + CD11b + cells. (Fig. 2C) . We reported that late sepsis Gr1 + CD11b + cells are immunosuppressive producers of IL-10 (MDSCs) and inhibit T cell proliferation and activation (Brudecki et al., 2012; McClure et al., 2016) . Here, septic control mice transfected with empty vector, Gr1 + CD11b + cells from the C/EBPβ conditional knockout mice reciprocally produced more TNFα and less IL-10 and did not suppress CD4 + T cell proliferation or IFNγ production (Fig. 3) . Moreover, ectopic expression of C/EBPβ reprogrammed these cells into the immunosuppressive phenotype (Fig. 3) . Together, these results demonstrate that C/EBPβ plays a pivotal role in supporting miR-21 and miR-181b expression in Gr1 + CD11b + immunosuppressive cells during sepsis. J. Dai et al. Molecular Immunology 91 (2017) 165-172 3.3. C/EBPβ primarily generates immunosuppressive Gr1 + CD11b + MDSCs in sepsis by inducing miR-21 and miR-181b
Results
Expression of miR-21 and miR-181b is lost in C/
C/EBPβ plays an essential role in limiting Gr1
We next investigated the essential role of miR-21 and miR-181b in generating immunosuppressive Gr1 +
CD11b
+ cells in sepsis, using C/ EBPβ-deficient cells without miR-21 and miR-181b expression (Fig. 1  A) . Transfection of miR-21 and miR-181b precursors elevated both miRNAs to a level even higher than C/EBPβ-expressing mice and subsequently attenuated their differentiation into macrophages and dendritic cells (Fig. 4) . We then examined Gr1 diminished the TNFα levels and increased IL-10 production ( Fig. 5A ) and repressed CD4 + T cell proliferation and activation, as demonstrated by IFNγ production (Fig. 5B) . Transfection with precursors of either miRNA alone did not elicit any significant effects (data not shown). These data support that, miR-21 and miR-181b expression is dominant and lies downstream of C/EBPβ in generating Gr1 + CD11b + MDSCs.
C/EBPβ conditional knockout reverses the immunosuppressive Gr1
+ CD11b + MDSC development during sepsis
We previously reported that NFI-A induction by miR-21 and miR181b drives Gr1 + CD11b + MDSC development in sepsis (McClure et al., 2016) , by a complex pathway involving cyclin-dependent kinase (cdk4) and its inhibitor p21, PTEN, and NF-kB proteins (McClure et al., 2016) . Here, we show that NFI-A expression was completely inhibited in the C/ EBPβ-deficient cells with increased p21 levels, similar to cells from sham mice (Fig. 6A) . Furthermore, reversing NFI-A and p21 expression patterns disrupted cdk4 protein complex and inactivated NF-kB (Fig. 6B) , a terminal supporter of Gr1 + CD11b + cell expansion (McClure et al., 2016) . Thus, C/EBPβ is a key and proximally drives Gr1 + CD11b + MDSC development in sepsis.
We also examined the p-Stat3 and miRNA levels in the presence or absence of exogeneous C/EBPβ protein. Both total and phosphorylated (active) Stat3 were expressed in the C/EBPβ-deficient cells (data not shown), and ectopic expression of C/EBPβ did not affect p-Stat3 levels, and meantime activated the miR-21 and miR-181b expressions (Fig. 7A) . To confirm the above results, we ectopically expressed the C/ EBPβ protein in sepsis C/EBPβ-deficient cells with or without Stat3 knockdown. As shown in Fig. 7B , lack of p-Stat3 prevented the miR-21 and miR-181b expression, despite the presence of the C/EBPβ protein.
These results extend our previous findings of a synergism between pStat3 and C/EBPβ for supporting miR-21 and miR-181b expressions.
Discussion
We previously reported that C/EBPβ plays an essential and proximal role in generating immunosuppressive Gr1 +
CD11b
+ myeloid cells (McClure et al., 2017; McPeak et al., 2017) . Taking a genetic approach, we confirm and extend support of the concept that C/EBPβ epigenetically controls miR-21 and miR-181b expression to drive MDSC reprogramming to the repressor phenotype so important in sepsis outcome. infection with many microbes, including fungi (Hotchkiss et al., 2013a,b) . Since late/chronic sepsis survival correlates with resolution of the immunosuppressive state, this study supports C/EBPβ targeting as a novel therapy for improving human sepsis outcomes. Most human sepsis deaths occur during the late stage of sepsis (Hotchkiss et al., 2013a; Mira et al., 2017) . Steady-state myelopoiesis maintains innate immunity cells (Ueda et al., 2005) . However, sepsis accelerates myelopoiesis. The rapid mobilization of innate immunity cells, especially granulocytes, from the bone marrow in response to the microbial products and damage-associated molecular patterns creates niches in the bone marrow (Manz et al., 2014; Ueda et al., 2005) , which under the stress of sepsis preferentially differentiate toward the myeloid lineage and more immature (progenitor) myeloid cells accumulate (Furze and Rankin, 2008; Manz et al., 2014) . While this "emergency" myelpoiesis may aim to repopulate the innate immune system, in sepsis the cells do not mature normally. Because MDSCs are intermediate between myeloid progenitors arising from the hematopoietic stem cells and mature myeloid cells, a block in differentiation and maturation may account for MDSC generation (Dilek et al., 2012; Gabrilovich and Nagaraj, 2009; Talmadge and Gabrilovich, 2013) . We have identified C/EBPβ as a key checkpoint for arresting Gr1 +
+ cells differentiation and maturation and promoting immune repressor cells. The numbers of the myeloid progenitors in the C/EBPβ conditional knockout mice are similar to the control, C/EBPβ-expressing mice (McPeak et al., 2017) , suggesting that C/EBPβ is not involved in the steady-state myelopoieis during sepsisdriven immune suppression. The molecular pathway triggered by C/EBPb during sepsis (depicted in Fig. 8 ) couples to miR 21 and miR181b. MiR-21 and miR-181b expression in Gr1 + CD11b + cells acts distal to C/EBPβ during sepsis to arrest differentiation and maturation (McClure et al., 2014) . Mechanistically, C/EBPβ, jointly with p-Stat3, bind to and activate the miR-21 and miR-181b promoters (McClure et al., 2017) . In line with this, expression of miR-21 and miR-181b was inhibited in C/EBPβ-deficient cells. In addition, we have previously shown that C/EBPβ and p-Stat3 proteins binds the miRNA promoters in a single complex (McClure et al., 2017) . Together these data identify an epigenetic cooperative that includes NF-kB/RelB to silence selective genes by forming heterochromatin McCall et al., 2010; Chen et al., 2009) . Importantly, this epigenetic reprogram is reversible and can be a target for promoting sepsis resolution. There are potential extensions and implications of this study. Immunosuppression with disrupted development and differentiation of innate and adaptive immunity is a major part of sepsis, but the latest sepsis III 2016 conference report places organ failure as a primary cause of death and dysregulated inflammation and immunity as a major contributor (Singer et al., 2016) . It will be important to determine if the C/EBPβ pathway, a ubiquitous transcription factor, disrupts organ physiology during sepsis.
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